Table II.
No. and Cumulative Proportion (%) of Patients Achieving Mean SeBP Goalsa
| Treatment | Denominator (No.) | SBP/DBP Goals, mm Hg | |||
|---|---|---|---|---|---|
| <140/90 | <130/85 | <130/80 | <120/80 | ||
| Olmesartan medoxomil 20 mg/d | Efficacy cohort (176) | 34 (19.3) | 13 (7.4) | 13 (7.4) | 3 (1.7) |
| Olmesartan medoxomil 40 mg/d | Efficacy cohort (176) | 58 (33.0) | 27 (15.3) | 27 (15.3) | 9 (5.1) |
| Olmesartan medoxomil/HCTZ 40/12.5 mg/d | Efficacy cohort (176) | 92 (52.3) | 57 (32.4) | 55 (31.3) | 27 (15.3) |
| Olmesartan medoxomil/HCTZ 40/25 mg/d | Efficacy cohort (176) | 118 (67.0) | 78 (44.3) | 75 (42.6) | 35 (19.9) |
Abbreviations: DBP, diastolic blood pressure; HCTZ, hydrochlorothiazide; SBP, systolic blood pressure; SeBP, seated blood pressure. aData for efficacy cohort include the cumulative number (%) within the efficacy cohort who achieved blood pressure goal at each possible titration point, regardless of treatment allocation at that time.